System, method and apparatus for electrosurgical instrument with movable fluid delivery sheath

Information

  • Patent Grant
  • 8323279
  • Patent Number
    8,323,279
  • Date Filed
    Friday, September 25, 2009
    15 years ago
  • Date Issued
    Tuesday, December 4, 2012
    12 years ago
Abstract
An electrosurgical instrument with a movable fluid delivery sheath assembly for variable fluid supply during surgical procedures is disclosed. The instrument comprises at least one active electrode and at least one return electrode, positioned on the instrument distal end. The sheath assembly has an outer sheath that is external to the instrument shaft, to provide a lumen. The sheath assembly lumen is axially movable between first and second positions relative to a fluid delivery element, for varying target site treatment and fluid delivery. In the first position the shaft distal end is axially distal to a leading edge of the sheath assembly. In the second position the sheath assembly distal leading edge is positioned axially adjacent or distal to the end of the shaft. The fluid delivery element comprises an inner lumen extending through at least a portion of the shaft, and at least one port extending radially through the shaft. The port is in communication with the inner lumen. A fluid supply source provides fluid through the port, sheath lumen and inner lumen.
Description
TECHNICAL FIELD

The present disclosure relates in general to electrosurgical instruments and, in particular, to an electrosurgical instrument with a fluid delivery device for controllably supplying fluid to a treatment site. More particularly, the present disclosure relates to a system, method and apparatus for an electrosurgical instrument having active and return electrodes with a movable fluid delivery sheath for variable fluid supply during surgical procedures.


DESCRIPTION OF THE RELATED ART

In some electrosurgical procedures an instrument (see, e.g., U.S. Pat. Nos. 5,683,366 and 6,235,020, which are incorporated herein by reference) has an active electrode and a return electrode that are used to treat body tissue. Treatment with this instrument may include, for example, coagulation, cutting, ablating, abrading or puncturing the tissue. In various designs, a current path is created between the active and return electrodes, thereby generating a limited plasma field between the electrodes and applying the plasma to the tissue, preferably without passing the current through the tissue. The current path may be created by providing an electrically conductive fluid at the target, or in some instances immersing the target site within electrically conductive fluid. It is preferred that the electrically conductive fluid has sufficient conductivity such that the fluid is ionized when subject to sufficient radio frequency (RF) electrical energy to thereby form the limited plasma. The conductive fluid path is an electrolyte, such as saline, lactated ringers solution, or conductive gels. One of the electrodes, referred to as the active electrode, is designed to generate a higher current density relative to other electrode, which is referred to as the return electrode. The source of the current is a high frequency voltage applied across the electrodes.


In some electrosurgical procedures an electrosurgical instrument (see, e.g., U.S. Pat. Nos. 6,159,208, 6,203,542 6,432,103 and 6,544,261 which are incorporated herein by reference) has at least two active electrode including at least one ablation electrode, at least one coagulation electrode and a return electrode that is used to treat body tissue and more particularly these instruments are operable to create a channel or hole into the target tissue. The present disclosure may include an instrument that is capable of performing a channeling technique in which small holes or channels are formed within tissue structures in the mouth, such as the tonsils, tongue, palate and uvula, and thermal energy is applied to the tissue surface immediately surrounding these holes or channels to cause thermal damage to the tissue surface, thereby stiffening the surrounding tissue structure. Applicant has discovered that such stiffening of certain tissue structures in the mouth and throat helps to prevent the tissue structure from obstructing the patient's upper airway during sleep. It is preferred that an electrically conductive fluid has sufficient conductivity such that the fluid is ionized when subject to sufficient radio frequency (RF) electrical energy to thereby form a limited plasma during use of the channeling instrument described above.


Although separate or additional fluid delivery systems may be employed for such applications described above, they add significant cost and complication to such procedures, while requiring multiple fluid delivery lines and crowding of the surgical area. Thus, an improved solution that overcomes the limitations of the prior art would be desirable.


BRIEF SUMMARY OF THE INVENTION

Embodiments of a system, method, and apparatus for an electrosurgical instrument having at least one active and at least one return electrode with a movable fluid delivery sheath for variable fluid supply during surgical procedures are disclosed. The electrosurgical fluid delivery apparatus has an outer sheath that is external to a shaft to provide an annular fluid delivery channel or lumen. The sheath assembly is axially slidable and movable relative to the fluid delivery element between first and second positions for treating the target site and controllable fluid delivery, respectively. The first position comprises positioning the distal leading edge of the sheath assembly axially proximal to the electrode assembly. The second position may comprise positioning the distal leading edge of the sheath assembly axially adjacent to the distal end of the shaft, or axially distal to the distal end of the shaft.


The fluid delivery element comprises an inner lumen extending through a portion of the shaft, and at least one port extending radially through the shaft. The at least one port is in fluid communication with the inner lumen. A fluid source may be connected to the inner lumen for providing fluid through the inner lumen and port. In one embodiment, the sheath assembly comprises a tube that is slidably movable relative to and concentric with the shaft. The tube defines an annular space or outer lumen between the tube and the shaft and has a radial seal. The radial seal is disposed between an outer surface of the shaft and an inner surface of the tube and sealingly engages the shaft and the tube.


In another embodiment, the sheath assembly has a range of motion between the first and second positions that provides a variable level of fluid delivery in the vicinity of the electrode assembly. Preferably, the sheath assembly is movable to provide a minimal level of fluid delivery proximate the electrode assembly in the first position, to a maximum level of fluid delivery adjacent to the electrode assembly in the second position. The fluid delivery element comprises an inner lumen extending through a portion of the shaft, and first and second plurality of ports extending radially through the shaft in fluid communication with the inner lumen. The first and second plurality of ports are preferably axially spaced apart. A fluid source may be connected to the outer lumen proximal to the radial seal. When the sheath assembly is in an intermediate or second position, the fluid source may provide a sequential fluid path through the outer lumen that is proximal to the radial seal, the first plurality of ports, to the second plurality of ports via the inner lumen and finally out through the outer lumen that is distal to the radial seal.


This disclosure may further comprise a method for treating tissue including the steps of positioning an active electrode adjacent to tissue and positioning a sheath assembly in a first position. The first position creates a delivery region that is proximal to the active electrode. A first high frequency voltage is then applied between the active electrode and a return electrode, and while this voltage is being applied, fluid may be delivered to the region proximal to the active electrode. The sheath assembly may then be advanced to a second position, the second position creating a fluid delivery region adjacent to the active electrode. A second high frequency voltage between the first active electrode and return electrode is then applied while delivering fluid to the region adjacent to the active electrode. The first and the second voltages levels may be substantially similar.


This disclosure may further comprise a method for creating a channel into tissue including the steps of positioning an electrode assembly comprising a first active electrode, a return electrode and a coagulation electrode adjacent to the target tissue. A sheath assembly is then retracted, the sheath assembly being disposed adjacent to a fluid delivery element, and wherein the retracting step may provide at least a portion of electrically conductive fluid at a position axially spaced away from the first active electrode. A first high frequency voltage is then applied between the first active electrode and the return electrode and during at least a portion of the applying step, the active electrode is advanced into the tissue, thereby creating a channel or hole in the tissue. At the same time or sequential to applying the first voltage, a second high frequency voltage may also be applied between the return electrode and the coagulation electrode. The electrode assembly may then be retracted from the channel and the sheath assembly may be advanced so as to provide at least a portion of the electrically conductive fluid at a position adjacent to the electrode assembly. A third high frequency may then be applied between the first active electrode and the return electrode to ablate the surface of the tissue. The first, second and third high frequency levels may all be substantially similar.


The foregoing and other objects and advantages of the present disclosure will be apparent to those skilled in the art, in view of the following detailed description of the present invention, taken in conjunction with the appended claims and the accompanying drawings.





BRIEF DESCRIPTION OF THE DRAWINGS

So that the manner in which the features and advantages of the present disclosure are attained and can be understood in more detail, a more particular description of the apparatus and methods briefly summarized above may be had by reference to the embodiments thereof that are illustrated in the appended drawings. However, the drawings illustrate only some embodiments of this disclosure and therefore are not to be considered limiting of its scope as the disclosure may admit to other equally effective embodiments.



FIG. 1 is a sectional side view of one embodiment of an electrosurgical instrument shown in a first position and is constructed according to the teachings of the present disclosure;



FIG. 2 is a sectional side view of the electrosurgical instrument of FIG. 1, shown in a second position, and is constructed according to the teachings of the present disclosure;



FIGS. 3-5 are sectional side views of another embodiment of an electrosurgical instrument shown in three different positions and is constructed according to the teachings of the present disclosure;



FIGS. 6 and 7 are enlarged schematic sectional side views of the electrosurgical instrument of FIGS. 3-5 in operation and is constructed according to the teachings of the present disclosure;



FIG. 8 is a schematic diagram of one embodiment of a system for operating an electrosurgical instrument and is constructed according to the teachings of the present disclosure;



FIG. 9 is a side view of one embodiment of an electrosurgical instrument, constructed according to the teachings of the present disclosure;



FIG. 10 shows a method of using an electrosurgical instrument embodiment described in the present disclosure; and



FIG. 11 shows a method of channeling into tissue in accordance with at least some embodiments.





DETAILED DESCRIPTION

Before the present disclosure is described in detail, it is to be understood that this is not limited to particular variations set forth herein as various changes or modifications may be made to the disclosure described and equivalents may be substituted without departing from the spirit and scope of the invention. As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process act(s) or step(s) to the objective(s), spirit or scope of the present invention. All such modifications are intended to be within the scope of the claims made herein.


Methods recited herein may be carried out in any order of the recited events which is logically possible, as well as the recited order of events. Furthermore, where a range of values is provided, it is understood that every intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein.


All existing subject matter mentioned herein (e.g., publications, patents, patent applications and hardware) is incorporated by reference herein in its entirety except insofar as the subject matter may conflict with that of the present disclosure (in which case what is present herein shall prevail). The referenced items are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present is not entitled to antedate such material by virtue of prior invention.


Reference to a singular item, includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation. Last, it is to be appreciated that unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.


The treatment device of the present disclosure may have a variety of configurations as described above. However, one variation employs a treatment device using Coblation® technology.


As stated above, the assignee of the present disclosure developed Coblation® technology. Coblation® technology involves the application of a high frequency voltage difference between one or more active electrode(s) and one or more return electrode(s) to develop high electric field intensities in the vicinity of the target tissue. The high electric field intensities may be generated by applying a high frequency voltage that is sufficient to vaporize an electrically conductive fluid over at least a portion of the active electrode(s) in the region between the tip of the active electrode(s) and the target tissue. The electrically conductive fluid may be a liquid or gas, such as isotonic saline, blood, extracelluar or intracellular fluid, delivered to, or already present at, the target site, or a viscous fluid, such as a gel, applied to the target site.


When the conductive fluid is heated enough such that atoms vaporize off the surface faster than they recondense, a gas is formed. When the gas is sufficiently heated such that the atoms collide with each other causing a release of electrons in the process, an ionized gas or plasma is formed (the so-called “fourth state of matter”). Generally speaking, plasmas may be formed by heating a gas and ionizing the gas by driving an electric current through it, or by shining radio waves into the gas. These methods of plasma formation give energy to free electrons in the plasma directly, and then electron-atom collisions liberate more electrons, and the process cascades until the desired degree of ionization is achieved. A more complete description of plasma can be found in Plasma Physics, by R. J. Goldston and P. H. Rutherford of the Plasma Physics Laboratory of Princeton University (1995), the complete disclosure of which is incorporated herein by reference.


As the density of the plasma or vapor layer becomes sufficiently low (i.e., less than approximately 1020 atoms/cm3 for aqueous solutions), the electron mean free path increases to enable subsequently injected electrons to cause impact ionization within the vapor layer. Once the ionic particles in the plasma layer have sufficient energy, they accelerate towards the target tissue. Energy evolved by the energetic electrons (e.g., 3.5 eV to 5 eV) can subsequently bombard a molecule and break its bonds, dissociating a molecule into free radicals, which then combine into final gaseous or liquid species. Often, the electrons carry the electrical current or absorb the radio waves and, therefore, are hotter than the ions. Thus, the electrons, which are carried away from the tissue towards the return electrode, carry most of the plasma's heat with them, allowing the ions to break apart the tissue molecules in a substantially non-thermal manner.


By means of this molecular dissociation (rather than thermal evaporation or carbonization), the target tissue structure is volumetrically removed through molecular disintegration of larger organic molecules into smaller molecules and/or atoms, such as hydrogen, oxygen, oxides of carbon, hydrocarbons and nitrogen compounds. This molecular disintegration completely removes the tissue structure, as opposed to dehydrating the tissue material by the removal of liquid within the cells of the tissue and extracellular fluids, as is typically the case with electrosurgical desiccation and vaporization. A more detailed description of this phenomena can be found in commonly assigned U.S. Pat. No. 5,697,882 the complete disclosure of which is incorporated herein by reference.


In some applications of the Coblation® technology, high frequency (RF) electrical energy is applied in an electrically conducting media environment to shrink or remove (i.e., resect, cut, or ablate) a tissue structure and to seal transected vessels within the region of the target tissue. Coblation® technology is also useful for sealing larger arterial vessels, e.g., on the order of about 1 mm in diameter. In such applications, a high frequency power supply is provided having an ablation mode, wherein a first voltage is applied to an active electrode sufficient to effect molecular dissociation or disintegration of the tissue, and a coagulation mode, wherein a second, lower voltage is applied to an active electrode (either the same or a different electrode) sufficient to heat, shrink, and/or achieve hemostasis of severed vessels within the tissue.


The amount of energy produced by the Coblation® device may be varied by adjusting a variety of factors, such as: the number of active electrodes; electrode size and spacing; electrode surface area; asperities and sharp edges on the electrode surfaces; electrode materials; applied voltage and power; current limiting means, such as inductors; electrical conductivity of the fluid in contact with the electrodes; density of the fluid; and other factors. Accordingly, these factors can be manipulated to control the energy level of the excited electrons. Since different tissue structures have different molecular bonds, the Coblation® device may be configured to produce energy sufficient to break the molecular bonds of certain tissue but insufficient to break the molecular bonds of other tissue. For example, fatty tissue (e.g., adipose) has double bonds that require an energy level substantially higher than 4 eV to 5 eV (typically on the order of about 8 eV) to break. Accordingly, the Coblation® technology generally does not ablate or remove such fatty tissue; however, it may be used to effectively ablate cells to release the inner fat content in a liquid form. Of course, factors may be changed such that these double bonds can also be broken in a similar fashion as the single bonds (e.g., increasing voltage or changing the electrode configuration to increase the current density at the electrode tips). A more complete description of this phenomena can be found in commonly assigned U.S. Pat. Nos. 6,355,032, 6,149,120 and 6,296,136, the complete disclosures of which are incorporated herein by reference.


The active electrode(s) of a Coblation® device may be supported within or by an inorganic insulating support positioned near the distal end of the instrument shaft. The return electrode may be located on the instrument shaft, on another instrument or on the external surface of the patient (i.e., a dispersive pad). The proximal end of the instrument(s) will include the appropriate electrical connections for coupling the return electrode(s) and the active electrode(s) to a high frequency power supply, such as an electrosurgical generator.


In one example of a Coblation® device for use with the present disclosure, the return electrode of the device is typically spaced proximally from the active electrode(s) a suitable distance to avoid electrical shorting between the active and return electrodes in the presence of electrically conductive fluid. In many cases, the distal edge of the exposed surface of the return electrode is spaced about 0.5 mm to 25 mm from the proximal edge of the exposed surface of the active electrode(s), preferably about 1.0 mm to 5.0 mm. Of course, this distance may vary with different voltage ranges, conductive fluids, and depending on the proximity of tissue structures to active and return electrodes. The return electrode will typically have an exposed length in the range of about 1 mm to 20 mm.


A Coblation® treatment device for use according to the present disclosure may use a single active electrode or an array of active electrodes spaced around the distal surface of a catheter or probe. In the latter embodiment, the electrode array usually includes a plurality of independently current-limited and/or power-controlled active electrodes to apply electrical energy selectively to the target tissue while limiting the unwanted application of electrical energy to the surrounding tissue and environment resulting from power dissipation into surrounding electrically conductive fluids, such as blood, normal saline, and the like. The active electrodes may be independently current-limited by isolating the terminals from each other and connecting each terminal to a separate power source that is isolated from the other active electrodes. Alternatively, the active electrodes may be connected to each other at either the proximal or distal ends of the catheter to form a single wire that couples to a power source.


In one configuration, each individual active electrode in the electrode array is electrically insulated from all other active electrodes in the array within the instrument and is connected to a power source which is isolated from each of the other active electrodes in the array or to circuitry which limits or interrupts current flow to the active electrode when low resistivity material (e.g., blood, electrically conductive saline irrigant or electrically conductive gel) causes a lower impedance path between the return electrode and the individual active electrode. The isolated power sources for each individual active electrode may be separate power supply circuits having internal impedance characteristics which limit power to the associated active electrode when a low impedance return path is encountered. By way of example, the isolated power source may be a user selectable constant current source. In this embodiment, lower impedance paths will automatically result in lower resistive heating levels since the heating is proportional to the square of the operating current times the impedance. Alternatively, a single power source may be connected to each of the active electrodes through independently actuatable switches, or by independent current limiting elements, such as inductors, capacitors, resistors and/or combinations thereof. The current limiting elements may be provided in the instrument, connectors, cable, controller, or along the conductive path from the controller to the distal tip of the instrument. Alternatively, the resistance and/or capacitance may occur on the surface of the active electrode(s) due to oxide layers which form selected active electrodes (e.g., titanium or a resistive coating on the surface of metal, such as platinum).


The Coblation® device is not limited to electrically isolated active electrodes, or even to a plurality of active electrodes. For example, the array of active electrodes may be connected to a single lead that extends through the catheter shaft to a power source of high frequency current.


The voltage difference applied between the return electrode(s) and the active electrode(s) will be at high or radio frequency, typically between about 5 kHz and 20 MHz, usually being between about 30 kHz and 2.5 MHz, preferably being between about 50 kHz and 500 kHz, often less than 350 kHz, and often between about 100 kHz and 200 kHz. In some applications, applicant has found that a frequency of about 100 kHz is useful because the tissue impedance is much greater at this frequency. In other applications, such as procedures in or around the heart or head and neck, higher frequencies may be desirable (e.g., 400-600 kHz) to minimize low frequency current flow into the heart or the nerves of the head and neck.


The RMS (root mean square) voltage applied will usually be in the range from about 5 volts to 1000 volts, preferably being in the range from about 10 volts to 500 volts, often between about 150 volts to 400 volts depending on the active electrode size, the operating frequency and the operation mode of the particular procedure or desired effect on the tissue (i.e., contraction, coagulation, cutting or ablation.)


Typically, the peak-to-peak voltage for ablation or cutting with a square wave form will be in the range of 10 volts to 2000 volts and preferably in the range of 100 volts to 1800 volts and more preferably in the range of about 300 volts to 1500 volts, often in the range of about 300 volts to 800 volts peak to peak (again, depending on the electrode size, number of electrons, the operating frequency and the operation mode). Lower peak-to-peak voltages will be used for tissue coagulation, thermal heating of tissue, or collagen contraction and will typically be in the range from 50 to 1500, preferably 100 to 1000 and more preferably 120 to 400 volts peak-to-peak (again, these values are computed using a square wave form). Higher peak-to-peak voltages, e.g., greater than about 800 volts peak-to-peak, may be desirable for ablation of harder material, such as bone, depending on other factors, such as the electrode geometries and the composition of the conductive fluid.


As discussed above, the voltage is usually delivered in a series of voltage pulses or alternating current of time varying voltage amplitude with a sufficiently high frequency (e.g., on the order of 5 kHz to 20 MHz) such that the voltage is effectively applied continuously (as compared with, e.g., lasers claiming small depths of necrosis, which are generally pulsed about 10 Hz to 20 Hz). In addition, the duty cycle (i.e., cumulative time in any one second interval that energy is applied) is on the order of about 50% for the present disclosure, as compared with pulsed lasers which typically have a duty cycle of about 0.0001%.


The preferred power source of the present disclosure delivers a high frequency current selectable to generate average power levels ranging from several milliwatts to tens of watts per electrode, depending on the volume of target tissue being treated, and/or the maximum allowed temperature selected for the instrument tip. The power source allows the user to select the voltage level according to the specific requirements of a particular neurosurgery procedure, cardiac surgery, arthroscopic surgery, dermatological procedure, ophthalmic procedures, open surgery or other endoscopic surgery procedure. For cardiac procedures and potentially for neurosurgery, the power source may have an additional filter, for filtering leakage voltages at frequencies below 100 kHz, particularly voltages around 60 kHz. Alternatively, a power source having a higher operating frequency, e.g., 300 kHz to 600 kHz may be used in certain procedures in which stray low frequency currents may be problematic. A description of one suitable power source can be found in commonly assigned U.S. Pat. Nos. 6,142,992 and 6,235,020, the complete disclosure of both patents are incorporated herein by reference for all purposes.


The power source may be current limited or otherwise controlled so that undesired heating of the target tissue or surrounding (non-target) tissue does not occur. In a presently preferred embodiment of the present invention, current limiting inductors are placed in series with each independent active electrode, where the inductance of the inductor is in the range of 10 uH to 50,000 uH, depending on the electrical properties of the target tissue, the desired tissue heating rate and the operating frequency. Alternatively, capacitor-inductor (LC) circuit structures may be employed, as described previously in U.S. Pat. No. 5,697,909, the complete disclosure of which is incorporated herein by reference. Additionally, current-limiting resistors may be selected. Preferably, these resistors will have a large positive temperature coefficient of resistance so that, as the current level begins to rise for any individual active electrode in contact with a low resistance medium (e.g., saline irrigant or blood), the resistance of the current limiting resistor increases significantly, thereby minimizing the power delivery from said active electrode into the low resistance medium (e.g., saline irrigant or blood).


Referring now to FIGS. 1-8, embodiments of a system, method and apparatus for an electrosurgical instrument having at least one active electrode and a return electrode with a movable fluid delivery sheath for variable fluid delivery during surgical procedures are disclosed. FIGS. 1 and 2 illustrate one embodiment of an electrosurgical fluid delivery apparatus 21 having an outer sheath 23 and grip 24 that is external to an instrument shaft 25 to provide an annular fluid delivery channel 27 or lumen. The distal terminus 29 of outer sheath 23 defines an annular fluid egress at a moveable location relative to electrode assembly 32. In FIG. 1 distal terminal or distal leading edge 29 is shown proximal to electrode assembly 32.


The direction of flow of fluid during use of apparatus 21 is indicated by the arrows. Electrically conductive fluid supplied to the distal end of apparatus 21 forms a current flow path between active electrodes 362 or 380 and return electrode 360, and may facilitate generation of plasma in the vicinity of active electrodes 362 or 380, as described hereinabove. Provision of an electrically conductive fluid may be particularly valuable in a dry field situation (e.g., in situations where there is a paucity of native electrically conductive bodily fluids, such as blood, synovial fluid, etc.). The electrically conductive fluid may be aspirated or removed from the distal end of apparatus 21 by a separate device (not shown).


The fluid delivery apparatus 21 may deliver fluid to a target site. For example, during an electrosurgical ablative procedure, it may be desirable to deliver electrically conductive fluid, to the target site to control the rate of ablation. It may also be desirable not only to control the rate of fluid delivery but also the location or dispersion level of the fluid delivery relative to the tissue treatment site. For example, it may be desirably to have the fluid delivery directed closer to the tissue treatment site (as shown in FIG. 2.) or alternatively dispersed around the tissue target site area (as shown in FIG. 1). As described more so in the description above, the tissue effect and efficacy of any vapor layer may be altered by many factors, including but not limited to the quantity of fluid supplied but also the location or dispersion level of the fluid relative to the treatment site.


The outer sheath 23, or sheath assembly, may be disposed adjacent to the fluid delivery element 22. The sheath assembly 23 is axially movable relative to the fluid delivery element 22 between a first position (FIG. 1) for treating the target site with minimal fluid delivery which may be dispersed further away from the target site and a second position (FIG. 2) for increased fluid delivery, where the fluid may also be directed closer to the target site. The first position may comprise positioning a distal leading edge 29 of the sheath assembly 23 axially proximal to the electrode assembly 32 or the distal end portion 33 of the shaft 25. The second position may comprise positioning the distal leading edge 29 of the sheath assembly 23 axially adjacent to the distal end portion 33 of the shaft 25, or alternatively axially distal to the distal end portion 33 of the shaft 25.


The fluid delivery element 22 may comprise an inner lumen 35 extending through a portion of the shaft 25, and at least one port 37 (e.g., three shown) extending radially through the shaft 25. The port(s) 37 are in fluid communication with the inner lumen 35 as well as outer lumen 27, thereby creating a fluid delivery path in the annular space surrounding shaft 25 and defined by sheath assembly 23 and seals 41. A conductive fluid source 39 (shown schematically) is connected to the inner lumen 35 for providing fluid though inner lumen 35, though the port(s) 37 and via outer lumen 27 to the egress located at distal leading edge 29. The port 37 may comprise a plurality of ports that are located adjacent or slightly proximal to the distal end portion 33 of the shaft 25 and axially spaced from the electrode assembly 32.


In one embodiment, the sheath assembly 23 comprises a tube that is slidably movable relative to and concentric with the shaft 25. Grip 24 may be disposed on sheath assembly 23 in certain embodiments to provide an ergonomic interface for the user (e.g., with the user's finger) in order to ease movement and sliding of sheath assembly 23. The sheath 23 defines an annular space or outer lumen 27 between the tube and the shaft 25 and has at least one radial seal 41. The radial seal 41 is disposed between an outer surface of the shaft 25 and an inner surface of the sheath 23 and sealingly engages the shaft 25 and the sheath 23. The radial seal 41 may comprise a plurality of o-rings that are seated in an axial series of radial grooves 43 formed in the inner surface of the sheath 23, with the radial grooves 43 being axially spaced from each other.


In the first position illustrated in FIG. 1, sheath assembly 23 is positioned to create a relatively low rate of fluid delivery in proximity to the target site and the area in the vicinity of the electrode assembly 32. In this first position, minimal fluid is delivered to the electrode assembly area 32, as it disperses away from the target area and a less effective vapor layer may be formed around the electrode assembly 32. Sheath assembly 23 may be deployed in the first position illustrated in FIG. 1 if the user detects the ablative effect on the target tissue is too intense, as the decreased fluid delivery may mitigate the efficacy of the vapor layer and plasma formed at electrode assembly 32. Alternatively, in the second position illustrated in FIG. 2, edge 29 of sheath assembly 23 is positioned adjacent to or distal to electrode assembly 32 to create a larger fluid delivery field and a relatively higher delivery rate directed to the target site and in the vicinity of electrode assembly 32. In this second position, sheath assembly 23 is deployed for a considerable rate of delivery, to create a more effective vapor layer and potentially a more efficient tissue ablation.


Electrode assembly 32 illustrates an electrode assembly embodiment often used for forming holes or channels in the tissues such as turbinates, soft palate tissue, tongue or tonsils, with the methods described in detail below. Namely, a high frequency voltage difference is applied between active and return electrodes 362, 360, respectively, in the presence of an electrically conductive fluid such that an electric current passes from the active electrode 362, through the conductive fluid, to the return electrode 360. The voltage is sufficient to vaporize the fluid around active electrode assembly 32 to form a plasma with sufficient energy to effect molecular dissociation of the tissue. The distal end portion 33 is then axially advanced through the tissue as the tissue is removed by the plasma in front of the end portion 33. It may be desired in some procedures to increase the thermal damage caused to the tissue surrounding hole or channel to coagulate any blood vessels exposed during channeling. Electrical current is therefore then passed through coagulation electrode 380 and return electrodes 360, which both have relatively large, smooth exposed surfaces to minimize high current densities at their surfaces, which minimizes damage to the surface of hole or channel.


Referring now to the embodiments of FIGS. 3-7, instrument 121 including sheath assembly 123 may be provided with a range of motion between the first and second positions that provides a variable level of fluid delivery at variable dispersion levels. Sheath assembly 123 is preferably slidable between a first deployed position where a minimal level of fluid delivery occurs (FIGS. 3 and 6), to a second deployed position where a maximum level of fluid delivery (FIGS. 5 and 7). An intermediate level of fluid delivery is depicted in FIG. 4.


In these embodiments, the fluid delivery element 122 comprises an inner lumen 135 extending through a portion of the shaft 125, and may terminate at the distal port 137. First and second ports, 137 and 138 extend radially through the shaft 125 in fluid communication with the inner lumen 135. The first and second ports, 137 and 138 are located on or adjacent to opposite axial ends of the inner lumen 135. The sheath assembly 123 comprises a tube that is slidably movable relative to and concentric with the shaft 125. Grip 124 may be disposed on sheath assembly 123 in certain embodiments to provide an ergonomic interface for the user (e.g., with the user's finger) in order to ease movement and sliding of sheath assembly 123. The sheath 123 defines an annular space or outer lumen 127 between the sheath 123 and the shaft 125 and has at least one radial seal 141. The radial seal 141 is disposed in the outer lumen 127 between an outer surface of the shaft 125 and an inner surface of the sheath 123 and sealingly engages the shaft 125 and the tube 123.


A fluid source 139 (e.g., indicated schematically) is connected to the outer lumen 127b proximal to the radial seal 141. Referring now to FIG. 3, sheath assembly 123 is deployed such that seals 141 are disposed proximally of both the first and second ports 137, 138. In this configuration, no fluid delivery chamber is formed in the annular space between sheath assembly 123 and shaft 125 and distal seals 141, such that fluid delivery may be minimal. In this configuration, first and second ports, 137 and 138 are at the same pressure with no net fluid flow therebetween and thereby fluidly bypassed by way of seals 141 isolating the first and second ports, 137 and 138 from the fluid delivery chamber and the portion of outer lumen 127 connected to fluid source 139. When the sheath assembly 123 is in the intermediate position (FIG. 4) or in the second position (FIGS. 5 and 7), the fluid source 139 provides a sequential fluid delivery path through outer lumen 127b, proximal to seals 141, proximal ports 138, inner lumen 135, distal ports 137 and outer lumen 127a that is distal to the radial seal 141.


In the first position illustrated in FIGS. 3 and 6, sheath assembly 123 is positioned to create a relatively low rate of fluid delivery through inner lumen 135 to the target site and the area in the vicinity of the electrode terminal. Additionally, the relatively low fluid delivery rate in the vicinity of electrode assembly 132 inhibits the formation of an effective vapor layer and more efficient plasma for tissue treatment and ablation. Alternatively, in the second position illustrated in FIGS. 5 and 7, a distal edge of sheath assembly 123 is positioned adjacent to or distal to electrodes assembly 132 and in proximity to the target site to create more fluid being delivered to the target site and in vicinity of electrode assembly 132. As such, sheath assembly 123 is deployed for a considerable rate of fluid delivery and to focus the delivery of fluid to the target site and adjacent to electrode assembly 132. Further, sheath assembly 123 may be deployed in the second position illustrated in FIGS. 5 and 7 if the user detects the ablative effect on the target tissue is not sufficiently intense, as the increased fluid may improve the efficacy of the vapor layer and plasma formed at electrode assembly 132.



FIG. 6 also shows a schematic example of the electrode assembly 132 channeling into tissue. Sheath 123 is in the first position, so as to provide minimal fluid delivery in proximity to the electrode assembly 132. During channeling, ablative active electrode 362 may be used to create the channeling effect and coagulation electrode 380 may be activated to coagulate any blood vessels (not shown here) exposed during ablation. FIG. 7 shows a schematic of an electrosurgical instrument 121 treating target tissue at the tissue surface. The user may chose to apply energy through only one active electrode 362 as shown in this example.


Referring now to FIG. 8, an exemplary electrosurgical system 801 for treatment of tissue in “dry fields” is shown. System 801 also may be used in a “wet field,” i.e., the target site is immersed in electrically conductive fluid. However, this system is particularly useful in dry fields where the fluid is preferably delivered through an electrosurgical probe 821 to the target site. As shown, electrosurgical system 801 generally comprises an electrosurgical hand piece or probe 821 connected to a power supply 803 for providing high frequency voltage to a target site and a fluid source 805 for supplying electrically conductive fluid 807 to probe 821. In addition, electrosurgical system 801 may include an endoscope (not shown) with a fiber optic head light for viewing the surgical site, particularly in sinus procedures or procedures in the ear or the back of the mouth. The endoscope may be integral with probe 821, or it may be part of a separate instrument. A fluid aspirator (not shown) may also be used to aspirate any fluid away from the surgical site.


As shown, probe 821 generally includes a proximal handle 811 and an elongate shaft 825 having an electrode assembly 832 at its distal end. A connecting cable 815 has a connector 816 for electrically coupling the electrodes assembly 832 to power supply 803. The electrode assembly 832 comprises at least two electrodes, that are electrically isolated from each other and each of the terminals is connected to an active or passive control network within power supply 803 by means of a plurality of individually insulated conductors (not shown). A fluid supply tube 817a may be connected to a fluid pump 840 which is then connected to fluid tube 818 via fluid supply tube 817b for supplying electrically conductive fluid 807 to the target site. Fluid tube 818 is fluidly coupled with an inner lumen (not shown here) of probe 821. Fluid pump 840 may comprise a positive displacement pump such as, for example, a peristaltic pump. The system 801 may also include a vacuum source as described herein that is coupled to a separate suction lumen or external tube for aspirating fluid from the target site. This suction lumen is not shown here.


Power supply 803 may comprise an operator controllable voltage level adjustment 819 to change the applied voltage level, which is observable at a voltage level display 821. Power supply 803 also includes first, second and third foot pedals 823, 825, 827 and a cable 829 that is removably coupled to power supply 803. The foot pedals 823, 825, 827 allow the surgeon to remotely adjust the energy level applied to electrode assembly 832. In an exemplary embodiment, first foot pedal 823 is used to place the power supply into the ablation mode and second foot pedal 825 places power supply 803 into the “coagulation” mode. The third foot pedal 827 allows the user to adjust the voltage level within the “ablation” mode.


In the ablation mode, a sufficient voltage is applied to the active electrodes to establish the requisite conditions for molecular dissociation of the tissue (i.e., vaporizing a portion of the electrically conductive fluid, ionizing charged particles within the vapor layer, and accelerating these charged particles against the tissue). As discussed above, the requisite voltage level for ablation will vary depending on the number, size, shape and spacing of the electrodes, the distance to which the electrodes extend from the support member, etc. Once the surgeon places the power supply in the ablation mode, voltage level adjustment 819 or third foot pedal 827 may be used to adjust the voltage level to adjust the degree or aggressiveness of the ablation.


Of course, it will be recognized that the voltage and modality of the power supply may be controlled by other input devices. However, applicant has found that foot pedals are convenient methods of controlling the power supply while manipulating the probe during a surgical procedure.


In the coagulation mode, the power supply 803 applies a low enough voltage to the active electrodes (or the coagulation electrode) to avoid vaporization of the electrically conductive fluid and subsequent molecular dissociation of the tissue. The surgeon may automatically toggle the power supply between the ablation and coagulation modes by alternately stepping on foot pedals 823, 825, respectively. This allows the surgeon to quickly move between coagulation and ablation in situ, without having to remove his/her concentration from the surgical field or without having to request an assistant to switch the power supply.


By way of example, as the surgeon is sculpting soft tissue in the ablation mode, the probe typically may simultaneously seal and/or coagulate small severed vessels within the tissue. However, larger vessels, or vessels with high fluid pressures (e.g., arterial vessels) may not be sealed in the ablation mode. Accordingly, the surgeon can simply actuate foot pedal 825, automatically lowering the voltage level below the threshold level for ablation, and apply sufficient pressure onto the severed vessel for a sufficient period of time to seal and/or coagulate the vessel. After this is completed, the surgeon may quickly move back into the ablation mode by actuating foot pedal 823.



FIG. 9 illustrates an embodiment of electrosurgical probe 350 incorporating an electrode assembly 372 having one or more active electrode(s) 362 and a proximally spaced return electrode 360. Return electrode 360 is typically spaced about 0.5 to 25 mm, preferably 1.0 to 5.0 mm from the active electrode(s) 362, and has an exposed length of about 1 to 20 mm. In addition, electrode assembly 372 may include a second active electrode 380 separated from return electrode 360 by an electrically insulating spacer 382. In this embodiment, handle 354 includes a switch 384 for toggling probe 350 between at least two different modes, an ablation mode and a subablation or thermal heating mode. In the ablation mode, voltage is applied between active electrode(s) 362 and return electrode 360 in the presence of some electrically conductive fluid, as described above. In the ablation mode, electrode 380 is deactivated. In the thermal heating or coagulation mode, active electrode(s) 362 may be deactivated and a voltage difference is applied between electrode 380 and electrode 360 such that a high frequency current 370 flows therebetween. Alternatively, active electrode(s) 362 may not be deactivated as the higher resistance of the smaller electrodes may automatically send the electric current to electrode 380 without having to physically decouple electrode(s) 362 from the circuit. In the thermal heating mode, a lower voltage is typically applied below the threshold for plasma formation and ablation, but sufficient to cause some thermal damage to the tissue immediately surrounding the electrodes without vaporizing or otherwise debulking this tissue so that the current 370 provides thermal heating and/or coagulation of tissue surrounding electrodes 360, 380.


Sheath assembly 323 is shown in a first position, wherein the fluid delivery region is proximal to the electrode assembly 372 and wherein minimal fluid is being delivered to the electrode assembly 372. Sheath 323 may be adjusted to alternate positions using grip 324, so as to deliver more fluid in alternate locations. A fluid source 339 (e.g., indicated schematically) is connected to the outer lumen 327, and in this first position shown in FIG. 9, minimal fluid may travel through lumen 327 due to the relative positions of the seals 341 and ports 338.


Referring now to FIG. 10, a method (1000) for treating tissue in accordance with at least some of the embodiments described herein is illustrated, including the steps of: positioning a first active electrode adjacent to tissue (1010); positioning a sheath assembly in a first position, the first position creating an fluid delivery region proximal to the first active electrode (1020); applying a first high frequency voltage between the first active electrode and a return electrode (1030); while applying the first high frequency voltage, delivering fluid to the region proximal to the first active electrode (1040); positioning the sheath assembly in a second position, the second position creating a delivery region adjacent to the active electrode (1050); applying a second high frequency voltage between the first active electrode and a return electrode (1060); while applying the second high frequency voltage, delivering fluid to the region adjacent to the active electrode (1070).


Referring now to FIG. 11, a method 1100 for creating a channel into tissue in accordance with at least some of the embodiments described herein is illustrated, including the steps of: positioning an electrode assembly comprising a first active electrode, a return electrode and a coagulation electrode adjacent to tissue (1110); retracting a sheath assembly disposed adjacent to a fluid delivery element, wherein the retracting step delivers at least a portion of electrically conductive fluid at a position axially spaced away from the first active electrode (1115); applying a first high frequency voltage between the first active electrode and the return electrode; during at least a portion of the applying step, advancing the active electrode into the tissue to create a channel (1120); applying a second high frequency voltage between the return electrode and coagulation electrode (1125); retracting the electrode assembly out of the channel (1130); advancing the sheath assembly disposed adjacent to the fluid delivery element, wherein the advancing step delivers at least a portion of the electrically conductive fluid at a position adjacent to the first active electrode (1035); and applying a high frequency between the first active electrode and the return electrode to ablate the surface of the tissue (1040).


While the invention has been shown or described in only some of its forms, it should be apparent to those skilled in the art that it is not so limited, but is susceptible to various changes without departing from the scope of the invention.

Claims
  • 1. A system for treating tissue, comprising: an electrosurgical instrument having a shaft with a proximal end and a distal end portion;an electrode assembly positioned on the distal end portion of the shaft comprising at least one active electrode and at least one return electrode axially spaced from the at least one active electrode;a fluid delivery element for delivering electrically conductive fluid to the active electrode comprising an inner lumen extending through a portion of the shaft, and first and second ports extending radially through the shaft in fluid communication with the inner lumen; anda sheath assembly disposed adjacently to the fluid delivery element and comprising at least one radial seal to sealingly engage the shaft and the sheath assembly, the sheath assembly being axially moveable relative to the fluid delivery element from a first position to a second position;wherein the fluid delivery element further comprises a fluid source connected to the sheath assembly proximal to the at least one radial seal and, when the sheath assembly is in the second position, the fluid source flows through a sequential fluid delivery path, through the sheath assembly proximal to the at least one radial seal, the first port, the inner lumen, the second port, the sheath assembly that is distal to the radial seal and via a distal opening disposed adjacent the electrode assembly.
  • 2. A system according to claim 1, wherein a distal leading edge of the sheath assembly is spaced axially proximal from the distal end portion of the shaft when the sheath assembly is in the first position, and the distal leading edge of the sheath assembly is disposed substantially axially adjacent to the distal end portion of the shaft when the sheath assembly is in the second position.
  • 3. A system according to claim 1, wherein the first port comprises a plurality of ports that are located axially adjacent the distal end portion of the shaft and axially spaced from the electrode assembly.
  • 4. A system according to claim 1, wherein the sheath assembly comprises a tube that is slidably movable relative to and concentric with the shaft, the tube defining an outer lumen between the tube and the shaft and the at least one radial seal being disposed between an outer surface of the shaft and an inner surface of the tube and sealingly engaging the shaft and the tube.
  • 5. A system according to claim 4, wherein the at least one radial seal comprises a plurality of o-rings that are seated in an axial series of radial grooves formed in the inner surface of the tube, the radial grooves being axially spaced from each other.
  • 6. A system according to claim 1, the first position operable to deliver fluid at a distance spaced away from the electrode assembly and the second position operable to deliver fluid adjacent to the active electrode.
  • 7. A system according to claim 1, wherein the sheath assembly has a range of motion between the first and second positions that provides a variable level of fluid delivery, from a minimal level of fluid delivery in the first position, to a maximum level of fluid delivery in the second position.
  • 8. A system for treating tissue, comprising: an electrosurgical instrument having a shaft with a proximal end and a distal end portion;an electrode assembly positioned on the distal end portion of the shaft comprising at least one active electrode and at least one return electrode axially spaced from the at least one active electrode;a fluid delivery element for delivering electrically conductive fluid to the active electrode; anda sheath assembly disposed adjacently to the fluid delivery element, the sheath assembly being axially moveable relative to the fluid delivery element from a first position to a second position;wherein the fluid delivery element comprises an inner lumen extending through a portion of the shaft, and first and second ports extending radially through the shaft in fluid communication with the inner lumen, the first and second ports axially spaced apart; andwherein the sheath assembly comprises a tube that is slidably movable relative to and concentric with the shaft, the tube defining an outer lumen between the tube and the shaft and having at least one radial seal, the at least one radial seal being disposed in the outer lumen between an outer surface of the shaft and an inner surface of the tube and sealingly engaging the shaft and the tube;and further comprising a fluid source connected to the outer lumen proximal to the radial seal and, when the sheath assembly is in the second position, the fluid source provides a sequential fluid delivery path through the outer lumen proximal to the radial seal, the first port, the inner lumen, the second port, the outer lumen that is distal to the radial seal and via a distal opening disposed at the distal end of the shaft.
  • 9. A system according to claim 1, wherein the first and second ports each comprise a plurality of ports, with the second port being located adjacent the distal end portion of the shaft and axially spaced from the electrode assembly, and the first port being located proximal to the second port.
  • 10. A system according to claim 1, wherein the electrode assembly comprises an ablation electrode and a coagulation electrode, wherein the ablation electrode and the coagulation electrode are spaced axially from the return electrode.
  • 11. An electrosurgical instrument for removing tissue from a target site within or on a patient's body comprising: a shaft having proximal and distal end portion;an electrode assembly comprising at least one active electrode positioned on the distal end portion of the shaft and a return electrode positioned on the shaft and axially spaced from the at least one active electrode;a fluid delivery element for delivering fluid to the target site, the fluid delivery element comprising an inner lumen disposed along a portion of the shaft and a first and second plurality of orts extending radially through the shaft, the plurality of ports in fluid communication with the inner lumen;a movable sheath assembly disposed adjacent to the shaft and defining an annular space around the shaft, the annular space having at least one radial seal disposed therein, the sheath assembly having a leading edge and being movable from a first position wherein the leading edge is retracted proximally from the electrode assembly to a second position wherein the leading edge is adjacent to the electrode assembly;wherein the first and second plurality of ports are fluidly bypassed in the first position.
  • 12. The electrosurgical instrument of claim 11, wherein the sheath assembly comprises a tube that is slidably movable relative to and concentric with the shaft, the tube defining an outer lumen between the tube and the shaft, the at least one radial seal being disposed between an outer surface of the shaft and an inner surface of the tube and sealingly engaging the shaft and the tube.
  • 13. An electrosurgical instrument for removing tissue from a target site within or on a patient's body comprising: a shaft having proximal and distal end portions;an electrode assembly comprising at least one active electrode positioned on the distal end portion of the shaft and a return electrode positioned on the shaft and axially spaced from the at least one active electrode;a movable sheath assembly disposed adjacent to the shaft and defining an annular space around the shaft, the sheath assembly having a leading edge and being movable from a first position wherein the leading edge is retracted proximally from the electrode assembly to a second position wherein the leading edge is adjacent to the electrode assembly, wherein the sheath assembly comprises a tube that is slidably movable relative to and concentric with the shaft, the tube defining an outer lumen between the tube and the shaft and having at least one radial seal, the at least one radial seal being disposed between an outer surface of the shaft and an inner surface of the tube and sealingly engaging the shaft and the tube;a fluid delivery element for delivering fluid to the target site; said delivery element comprising an inner lumen disposed along a portion of the shaft and a plurality of ports extending radially through the shaft, the plurality of ports in fluid communication with the inner lumen and the annular space;wherein the first and second plurality of ports are fluidly bypassed in the first position, and wherein the first and second plurality of ports are fluidly connected to the outer lumen proximal to at least one radial seal in the second position.
  • 14. A system according to claim 11, wherein the electrode assembly comprises at least one ablation electrode and at least one coagulation electrode located on the shaft, wherein the ablation electrode and the coagulation electrode are axially spaced from the return electrode.
  • 15. A system according to claim 11, wherein the sheath assembly further comprises a grip operable to slide the sheath assembly into position.
US Referenced Citations (544)
Number Name Date Kind
2050904 Trice Aug 1936 A
2056377 Wappler Oct 1939 A
2275167 Bierman Mar 1942 A
3633425 Sanford Jan 1972 A
3699967 Anderson Oct 1972 A
3812858 Oringer May 1974 A
3815604 O'Malley et al. Jun 1974 A
3828780 Morrison, Jr. et al. Aug 1974 A
3901242 Storz Aug 1975 A
3920021 Hiltebrandt Nov 1975 A
3939839 Curtiss Feb 1976 A
3945375 Banko Mar 1976 A
3970088 Morrison Jul 1976 A
4033351 Hetzel Jul 1977 A
4040426 Morrison, Jr. Aug 1977 A
4043342 Morrison, Jr. Aug 1977 A
4074718 Morrison, Jr. Feb 1978 A
4092986 Schneiderman Jun 1978 A
4116198 Roos Sep 1978 A
4181131 Ogiu Jan 1980 A
4184492 Meinke et al. Jan 1980 A
4202337 Hren et al. May 1980 A
4203444 Bonnell et al. May 1980 A
4228800 Degler, Jr. et al. Oct 1980 A
4232676 Herczog Nov 1980 A
4240441 Khalil Dec 1980 A
4248231 Herczog et al. Feb 1981 A
4269174 Adair May 1981 A
4326529 Doss et al. Apr 1982 A
4381007 Doss Apr 1983 A
4411266 Cosman Oct 1983 A
4429694 McGreevy Feb 1984 A
4474179 Koch Oct 1984 A
4476862 Pao Oct 1984 A
4483338 Bloom et al. Nov 1984 A
4532924 Auth et al. Aug 1985 A
4548207 Reimels Oct 1985 A
4567890 Ohta et al. Feb 1986 A
4582057 Auth et al. Apr 1986 A
4590934 Malis et al. May 1986 A
4593691 Lindstrom et al. Jun 1986 A
4641649 Walinsky Feb 1987 A
4658817 Hardy Apr 1987 A
4660571 Hess et al. Apr 1987 A
4674499 Pao Jun 1987 A
4675499 Nakai Jun 1987 A
4682596 Bales et al. Jul 1987 A
4706667 Roos Nov 1987 A
4709698 Johnston et al. Dec 1987 A
4719914 Johnson Jan 1988 A
4727874 Bowers et al. Mar 1988 A
4736743 Daikuzono Apr 1988 A
4737678 Hasegawa Apr 1988 A
4762128 Rosenbluth Aug 1988 A
4765331 Petruzzi et al. Aug 1988 A
4785806 Deckelbaum Nov 1988 A
4785823 Eggers et al. Nov 1988 A
4805616 Pao Feb 1989 A
4813429 Eshel et al. Mar 1989 A
4823791 D'Amelio et al. Apr 1989 A
4827911 Broadwin et al. May 1989 A
4832048 Cohen May 1989 A
4860752 Turner et al. Aug 1989 A
4903696 Stasz et al. Feb 1990 A
4907589 Cosman Mar 1990 A
4920978 Colvin May 1990 A
4931047 Broadwin et al. Jun 1990 A
4936281 Stasz Jun 1990 A
4936301 Rexroth et al. Jun 1990 A
4940064 Desai Jul 1990 A
4943290 Rexroth et al. Jul 1990 A
4955377 Lennox et al. Sep 1990 A
4966597 Cosman Oct 1990 A
4967765 Turner et al. Nov 1990 A
4968314 Michaels Nov 1990 A
4976709 Sand Dec 1990 A
4976711 Parins et al. Dec 1990 A
4979948 Geddes et al. Dec 1990 A
4998933 Eggers et al. Mar 1991 A
5007437 Sterzer Apr 1991 A
5007908 Rydell Apr 1991 A
5009656 Reimels Apr 1991 A
5035696 Rydell Jul 1991 A
5037421 Boutacoff et al. Aug 1991 A
5047026 Rydell Sep 1991 A
5047027 Rydell Sep 1991 A
5057105 Malone et al. Oct 1991 A
5057106 Kasevich et al. Oct 1991 A
5061266 Hakky Oct 1991 A
5078717 Parins et al. Jan 1992 A
5080660 Buelna Jan 1992 A
5083565 Parins Jan 1992 A
5084044 Quint Jan 1992 A
5084045 Helenowski Jan 1992 A
5085659 Rydell Feb 1992 A
5088997 Delahuerga et al. Feb 1992 A
5092339 Geddes et al. Mar 1992 A
5093877 Aita et al. Mar 1992 A
5098431 Rydell Mar 1992 A
5099840 Goble Mar 1992 A
5102410 Dressel Apr 1992 A
5103804 Abele et al. Apr 1992 A
5108391 Flachenecker et al. Apr 1992 A
RE33925 Bales et al. May 1992 E
5112330 Nishigaki et al. May 1992 A
5122138 Manwaring Jun 1992 A
5125928 Parins et al. Jun 1992 A
5137530 Sand Aug 1992 A
5147354 Boutacoff et al. Sep 1992 A
5151098 Loertscher Sep 1992 A
5156151 Imran Oct 1992 A
5167659 Ohtomo et al. Dec 1992 A
5171311 Rydell et al. Dec 1992 A
5176528 Fry et al. Jan 1993 A
5178620 Eggers et al. Jan 1993 A
5190517 Zieve et al. Mar 1993 A
5191883 Lennox et al. Mar 1993 A
5192280 Parins Mar 1993 A
5195959 Smith Mar 1993 A
5197466 Marchosky et al. Mar 1993 A
5197963 Parins Mar 1993 A
5207675 Canady May 1993 A
5217455 Tan Jun 1993 A
5217457 Delahuerga et al. Jun 1993 A
5217459 Kamerling Jun 1993 A
5230334 Klopotek Jul 1993 A
5234428 Kaufman Aug 1993 A
5246438 Langberg Sep 1993 A
5249585 Turner et al. Oct 1993 A
5261410 Alfano et al. Nov 1993 A
5267994 Gentelia et al. Dec 1993 A
5267997 Farin et al. Dec 1993 A
5269794 Rexroth Dec 1993 A
5273524 Fox et al. Dec 1993 A
5277201 Stern Jan 1994 A
5277696 Hagen Jan 1994 A
5279299 Imran Jan 1994 A
5281216 Klicek Jan 1994 A
5281218 Imran Jan 1994 A
5282797 Chess Feb 1994 A
5282799 Rydell Feb 1994 A
5290273 Tan Mar 1994 A
5290282 Casscells Mar 1994 A
5293868 Nardella Mar 1994 A
5295956 Bales et al. Mar 1994 A
5300069 Hunsberger et al. Apr 1994 A
5300099 Rudie Apr 1994 A
5301687 Wong et al. Apr 1994 A
5304169 Sand Apr 1994 A
5304170 Green Apr 1994 A
5306238 Fleenor Apr 1994 A
5312395 Tan et al. May 1994 A
5312400 Bales et al. May 1994 A
5314406 Arias et al. May 1994 A
5318563 Malis et al. Jun 1994 A
5322507 Costello et al. Jun 1994 A
5324254 Phillips Jun 1994 A
5330470 Hagen Jul 1994 A
5330518 Neilson et al. Jul 1994 A
5334140 Philips Aug 1994 A
5334183 Wuchinich Aug 1994 A
5334193 Nardella Aug 1994 A
5335668 Nardella Aug 1994 A
5336217 Buys et al. Aug 1994 A
5336220 Ryan et al. Aug 1994 A
5336443 Eggers Aug 1994 A
5342357 Nardella Aug 1994 A
5348554 Imran et al. Sep 1994 A
5366443 Odashima Nov 1994 A
5370642 Keller Dec 1994 A
5370644 Langberg Dec 1994 A
5370675 Edwards et al. Dec 1994 A
5374261 Yoon Dec 1994 A
5374265 Sand Dec 1994 A
5375588 Yoon Dec 1994 A
5380277 Phillips Jan 1995 A
5380316 Aita Jan 1995 A
5383876 Nardella Jan 1995 A
5383917 Desai et al. Jan 1995 A
5389096 Aita Feb 1995 A
5395312 Desai Mar 1995 A
5395363 Billings et al. Mar 1995 A
5400267 Denen et al. Mar 1995 A
5401272 Perkins Mar 1995 A
5403311 Abele et al. Apr 1995 A
5405376 Mulier et al. Apr 1995 A
5417687 Nardella et al. May 1995 A
5419767 Eggers et al. May 1995 A
5423803 Tankovich Jun 1995 A
5423810 Goble et al. Jun 1995 A
5423844 Miller Jun 1995 A
5423882 Jackman et al. Jun 1995 A
5431649 Mulier et al. Jul 1995 A
5432882 Glynn Jul 1995 A
5433708 Nichols et al. Jul 1995 A
5436566 Thompson et al. Jul 1995 A
5437662 Nardella Aug 1995 A
5437664 Cohen et al. Aug 1995 A
5438302 Goble Aug 1995 A
5441499 Fritzsch Aug 1995 A
5445634 Keller Aug 1995 A
5451224 Goble et al. Sep 1995 A
5454809 Janssen Oct 1995 A
5458596 Lax et al. Oct 1995 A
5462545 Wang et al. Oct 1995 A
5484435 Fleenor et al. Jan 1996 A
5487385 Avitall Jan 1996 A
5490850 Ellman et al. Feb 1996 A
5496312 Klicek Mar 1996 A
5496314 Eggers Mar 1996 A
5496317 Goble et al. Mar 1996 A
5505710 Dorsey, III Apr 1996 A
5514130 Baker May 1996 A
5520685 Wojciechowicz May 1996 A
5536267 Edwards et al. Jul 1996 A
5542928 Evans et al. Aug 1996 A
5545161 Imran Aug 1996 A
5554152 Aita Sep 1996 A
5556397 Long et al. Sep 1996 A
5562703 Desai Oct 1996 A
5569242 Lax et al. Oct 1996 A
5571100 Goble et al. Nov 1996 A
5579764 Goldreyer Dec 1996 A
5584872 LaFontaine et al. Dec 1996 A
5607391 Klinger et al. Mar 1997 A
5607421 Jeevanandam et al. Mar 1997 A
5609151 Mulier et al. Mar 1997 A
5626576 Janssen May 1997 A
5633578 Eggers et al. May 1997 A
5643255 Organ Jul 1997 A
5647869 Goble et al. Jul 1997 A
5653692 Masterson et al. Aug 1997 A
5660836 Knowlton Aug 1997 A
5662680 Desai Sep 1997 A
5676693 LaFontaine et al. Oct 1997 A
5681282 Eggers et al. Oct 1997 A
5681308 Edwards et al. Oct 1997 A
5683366 Eggers et al. Nov 1997 A
5688267 Panescu et al. Nov 1997 A
5697281 Eggers et al. Dec 1997 A
5697536 Eggers et al. Dec 1997 A
5697882 Eggers et al. Dec 1997 A
5697909 Eggers et al. Dec 1997 A
5700262 Acosta et al. Dec 1997 A
5713896 Nardella Feb 1998 A
5725524 Mulier et al. Mar 1998 A
5743870 Edwards Apr 1998 A
5743903 Stern et al. Apr 1998 A
5746746 Garito et al. May 1998 A
5749869 Lindenmeier et al. May 1998 A
5755753 Knowlton May 1998 A
5766153 Eggers et al. Jun 1998 A
5769843 Abela et al. Jun 1998 A
5769847 Panescu et al. Jun 1998 A
5782795 Bays Jul 1998 A
5785705 Baker Jul 1998 A
5800429 Edwards Sep 1998 A
5800431 Brown Sep 1998 A
5807384 Mueller Sep 1998 A
5807395 Mulier et al. Sep 1998 A
5810764 Eggers et al. Sep 1998 A
5810802 Panescu et al. Sep 1998 A
5810809 Rydell Sep 1998 A
5836875 Webster, Jr. Nov 1998 A
5843019 Eggers et al. Dec 1998 A
5843078 Sharkey Dec 1998 A
5855277 Apps et al. Jan 1999 A
5860951 Eggers Jan 1999 A
5860974 Abele Jan 1999 A
5860975 Goble et al. Jan 1999 A
5871469 Eggers et al. Feb 1999 A
5871524 Knowlton Feb 1999 A
5873855 Eggers et al. Feb 1999 A
5876398 Mulier et al. Mar 1999 A
5885277 Korth Mar 1999 A
5888198 Eggers et al. Mar 1999 A
5891095 Eggers et al. Apr 1999 A
5891134 Goble et al. Apr 1999 A
5893848 Negus et al. Apr 1999 A
5895386 Odell et al. Apr 1999 A
5897553 Mulier Apr 1999 A
5902272 Eggers et al. May 1999 A
5904681 West, Jr. May 1999 A
5906613 Mulier et al. May 1999 A
5919219 Knowlton Jul 1999 A
5944715 Goble et al. Aug 1999 A
5954716 Sharkey et al. Sep 1999 A
5964754 Osypka Oct 1999 A
5976127 Lax Nov 1999 A
5980516 Mulier et al. Nov 1999 A
5980545 Pacala et al. Nov 1999 A
5984919 Hilal et al. Nov 1999 A
6004319 Goble et al. Dec 1999 A
6007533 Casscells et al. Dec 1999 A
6007570 Sharkey et al. Dec 1999 A
6013076 Goble et al. Jan 2000 A
6015406 Goble et al. Jan 2000 A
6016809 Mulier et al. Jan 2000 A
6024733 Eggers et al. Feb 2000 A
6027501 Goble et al. Feb 2000 A
6030383 Benderev Feb 2000 A
6032673 Savage et al. Mar 2000 A
6032674 Eggers et al. Mar 2000 A
6039734 Goble et al. Mar 2000 A
6042580 Simpson Mar 2000 A
6045532 Eggers et al. Apr 2000 A
6047700 Eggers et al. Apr 2000 A
6053172 Hovda et al. Apr 2000 A
6056746 Goble et al. May 2000 A
6063079 Hovda et al. May 2000 A
6063081 Mulier et al. May 2000 A
6066134 Eggers et al. May 2000 A
6068628 Fanton et al. May 2000 A
6074386 Goble et al. Jun 2000 A
6090106 Goble et al. Jul 2000 A
6091995 Ingle et al. Jul 2000 A
6093186 Goble et al. Jul 2000 A
6096037 Mulier et al. Aug 2000 A
6102046 Weinstein et al. Aug 2000 A
6105581 Eggers et al. Aug 2000 A
6109268 Thapliyal et al. Aug 2000 A
6110169 Mueller et al. Aug 2000 A
6117109 Eggers et al. Sep 2000 A
6126682 Sharkey et al. Oct 2000 A
6142992 Cheng et al. Nov 2000 A
6149620 Baker et al. Nov 2000 A
6152923 Ryan Nov 2000 A
6156031 Aita et al. Dec 2000 A
6159194 Eggers et al. Dec 2000 A
6159208 Hovda et al. Dec 2000 A
6168593 Sharkey et al. Jan 2001 B1
6174309 Wrublewski et al. Jan 2001 B1
6179824 Eggers et al. Jan 2001 B1
6179836 Eggers et al. Jan 2001 B1
6183469 Thapliyal et al. Feb 2001 B1
6190381 Olsen et al. Feb 2001 B1
6203542 Ellsberry et al. Mar 2001 B1
6210402 Olsen et al. Apr 2001 B1
6210405 Goble et al. Apr 2001 B1
6214001 Casscells et al. Apr 2001 B1
6217575 DeVore et al. Apr 2001 B1
6224592 Eggers et al. May 2001 B1
6228078 Eggers May 2001 B1
6228081 Goble May 2001 B1
6234178 Eggers May 2001 B1
6235020 Cheng et al. May 2001 B1
6235023 Lee et al. May 2001 B1
6237604 Burnside et al. May 2001 B1
6238391 Olsen et al. May 2001 B1
6238393 Mulier et al. May 2001 B1
6254600 Willink et al. Jul 2001 B1
6261286 Goble et al. Jul 2001 B1
6261311 Sharkey et al. Jul 2001 B1
6264650 Hovda Jul 2001 B1
6264652 Eggers et al. Jul 2001 B1
6267757 Aita et al. Jul 2001 B1
6270460 McCartan et al. Aug 2001 B1
6277112 Underwood et al. Aug 2001 B1
6280441 Ryan Aug 2001 B1
6283961 Underwood et al. Sep 2001 B1
6293942 Goble et al. Sep 2001 B1
6296636 Cheng et al. Oct 2001 B1
6296638 Davison et al. Oct 2001 B1
6302903 Mulier et al. Oct 2001 B1
6306134 Goble et al. Oct 2001 B1
6308089 von der Rur et al. Oct 2001 B1
6309387 Eggers et al. Oct 2001 B1
6312408 Eggers et al. Nov 2001 B1
6312429 Butbank et al. Nov 2001 B1
6315774 Daniel et al. Nov 2001 B1
6322494 Bullivant et al. Nov 2001 B1
6322549 Eggers et al. Nov 2001 B1
6325799 Goble Dec 2001 B1
6327505 Medhkour et al. Dec 2001 B1
6328736 Mulier et al. Dec 2001 B1
6336926 Goble Jan 2002 B1
6346107 Cucin Feb 2002 B1
6355006 Ryaby et al. Mar 2002 B1
6355032 Hovda et al. Mar 2002 B1
6358248 Mulier et al. Mar 2002 B1
6363937 Hovda et al. Apr 2002 B1
6364877 Goble et al. Apr 2002 B1
6379350 Sharkey et al. Apr 2002 B1
6379351 Thapliyal et al. Apr 2002 B1
6391025 Weinstein et al. May 2002 B1
6391028 Fanton et al. May 2002 B1
6398781 Gobel et al. Jun 2002 B1
6409724 Penny et al. Jun 2002 B1
6416507 Eggers et al. Jul 2002 B1
6416508 Eggers et al. Jul 2002 B1
6416509 Goble et al. Jul 2002 B1
6432103 Ellsberry et al. Aug 2002 B1
6432105 Ellman et al. Aug 2002 B1
6468274 Alleyne et al. Oct 2002 B1
6468275 Wampler et al. Oct 2002 B1
6482201 Olsen et al. Nov 2002 B1
6482202 Goble et al. Nov 2002 B1
6491690 Gobel et al. Dec 2002 B1
6497705 Comben Dec 2002 B2
6497706 Burbank et al. Dec 2002 B1
6510854 Gobel Jan 2003 B2
6514250 Jahns et al. Feb 2003 B1
6517498 Burbank et al. Feb 2003 B1
6517535 Edwards Feb 2003 B2
6530922 Cosman Mar 2003 B2
6540741 Underwood et al. Apr 2003 B1
6557559 Eggers et al. May 2003 B1
6575968 Eggers et al. Jun 2003 B1
6575969 Rittman, III et al. Jun 2003 B1
6578579 Burnside Jun 2003 B2
6582423 Thapliyal et al. Jun 2003 B1
6589237 Woloszko et al. Jul 2003 B2
6595990 Weinstein et al. Jul 2003 B1
6597950 Linder et al. Jul 2003 B2
6602248 Sharps et al. Aug 2003 B1
6605085 Edwards Aug 2003 B1
6610059 West, Jr. Aug 2003 B1
6620156 Garito et al. Sep 2003 B1
6632193 Davison et al. Oct 2003 B1
6632220 Eggers et al. Oct 2003 B1
6632230 Barry Oct 2003 B2
6645203 Sharkey et al. Nov 2003 B2
6663628 Peters Dec 2003 B2
6695839 Sharkey et al. Feb 2004 B2
6699206 Burbank et al. Mar 2004 B2
6699244 Carranza et al. Mar 2004 B2
6702810 McClurken et al. Mar 2004 B2
6746447 Davison et al. Jun 2004 B2
6749604 Eggers et al. Jun 2004 B1
6749608 Garito et al. Jun 2004 B2
6763836 Tasto et al. Jul 2004 B2
6770071 Woloszko et al. Aug 2004 B2
6780178 Palanker et al. Aug 2004 B2
6780180 Goble et al. Aug 2004 B1
6796982 Carmel et al. Sep 2004 B2
6802842 Ellman et al. Oct 2004 B2
6805130 Tasto et al. Oct 2004 B2
6827725 Batchelor et al. Dec 2004 B2
6832996 Woloszko et al. Dec 2004 B2
6837887 Woloszko et al. Jan 2005 B2
6837888 Ciarrocca et al. Jan 2005 B2
6855143 Davison et al. Feb 2005 B2
6896674 Woloszko et al. May 2005 B1
6904303 Phan et al. Jun 2005 B2
6920883 Bessette et al. Jul 2005 B2
6929640 Underwood et al. Aug 2005 B1
6949096 Davison et al. Sep 2005 B2
6960204 Eggers et al. Nov 2005 B2
6974453 Woloszko et al. Dec 2005 B2
6979332 Adams Dec 2005 B2
6984231 Goble et al. Jan 2006 B2
6991631 Woloszko et al. Jan 2006 B2
7004941 Tvinnereim et al. Feb 2006 B2
7041102 Truckai et al. May 2006 B2
7070596 Woloszko et al. Jul 2006 B1
7090672 Underwood et al. Aug 2006 B2
7094215 Davison et al. Aug 2006 B2
7104986 Hovda et al. Sep 2006 B2
7131969 Hovda et al. Nov 2006 B1
7150747 McDonald et al. Dec 2006 B1
7169143 Eggers et al. Jan 2007 B2
7179255 Lettice et al. Feb 2007 B2
7184811 Phan et al. Feb 2007 B2
7186234 Dahla et al. Mar 2007 B2
7192428 Eggers et al. Mar 2007 B2
7201750 Eggers et al. Apr 2007 B1
7217268 Eggers et al. May 2007 B2
7241293 Davison Jul 2007 B2
7258690 Sutton et al. Aug 2007 B2
7261712 Burbank et al. Aug 2007 B2
7270658 Woloszko et al. Sep 2007 B2
7270659 Ricart et al. Sep 2007 B2
7270661 Dahla et al. Sep 2007 B2
7276063 Davison et al. Oct 2007 B2
7297143 Woloszko et al. Nov 2007 B2
7297145 Woloszko et al. Nov 2007 B2
7318823 Sharps et al. Jan 2008 B2
7331956 Hovda et al. Feb 2008 B2
RE40156 Sharps et al. Mar 2008 E
7357798 Sharps et al. Apr 2008 B2
7387625 Hovda et al. Jun 2008 B2
7419488 Ciarrocca et al. Sep 2008 B2
7429260 Underwood et al. Sep 2008 B2
7429262 Woloszko et al. Sep 2008 B2
7435247 Woloszko et al. Oct 2008 B2
7442191 Hovda et al. Oct 2008 B2
7445618 Eggers et al. Nov 2008 B2
7449021 Underwood et al. Nov 2008 B2
7462178 Woloszko et al. Dec 2008 B2
7468059 Eggers et al. Dec 2008 B2
7488295 Burbank et al. Feb 2009 B2
7491200 Underwood et al. Feb 2009 B2
7507236 Eggers et al. Mar 2009 B2
7572251 Davison et al. Aug 2009 B1
7819863 Eggers et al. Oct 2010 B2
20020029036 Goble et al. Mar 2002 A1
20020049438 Sharkey et al. Apr 2002 A1
20020072739 Lee et al. Jun 2002 A1
20030013986 Saadat Jan 2003 A1
20030088245 Woloszko et al. May 2003 A1
20030130655 Woloszko et al. Jul 2003 A1
20030130711 Pearson et al. Jul 2003 A1
20030158545 Hovda et al. Aug 2003 A1
20030171743 Tasto et al. Sep 2003 A1
20030208196 Stone Nov 2003 A1
20030212396 Eggers et al. Nov 2003 A1
20040116922 Hovda et al. Jun 2004 A1
20040127893 Hovda Jul 2004 A1
20040230190 Dahla et al. Nov 2004 A1
20050004634 Ricart et al. Jan 2005 A1
20050119650 Sanders et al. Jun 2005 A1
20050251134 Woloszko et al. Nov 2005 A1
20050261754 Woloszko et al. Nov 2005 A1
20050288665 Woloszko et al. Dec 2005 A1
20060036237 Davison et al. Feb 2006 A1
20060095031 Ormsby May 2006 A1
20060106379 O'Brien et al. May 2006 A1
20060178670 Woloszko et al. Aug 2006 A1
20060189971 Tasto et al. Aug 2006 A1
20060253117 Hovda et al. Nov 2006 A1
20060259025 Dahla Nov 2006 A1
20070005051 Kampa Jan 2007 A1
20070010808 Dahla Jan 2007 A1
20070106288 Woloszko et al. May 2007 A1
20070149966 Dahla et al. Jun 2007 A1
20070161981 Sanders et al. Jul 2007 A1
20070208334 Woloszko et al. Sep 2007 A1
20070208335 Woloszko et al. Sep 2007 A1
20070213700 Davison et al. Sep 2007 A1
20070282323 Woloszko et al. Dec 2007 A1
20080021447 Davison et al. Jan 2008 A1
20080167645 Woloszko Jul 2008 A1
20080167646 Godara et al. Jul 2008 A1
20080234673 Marion et al. Sep 2008 A1
20080300590 Horne et al. Dec 2008 A1
20090069807 Eggers et al. Mar 2009 A1
20090138011 Epstein May 2009 A1
20090209958 Davison et al. Aug 2009 A1
20100042095 Bigley et al. Feb 2010 A1
20100152724 Marion et al. Jun 2010 A1
20100204690 Bigley et al. Aug 2010 A1
20110077643 Dahla et al. Mar 2011 A1
20110270242 Marion Nov 2011 A1
20120179157 Frazier et al. Jul 2012 A1
Foreign Referenced Citations (113)
Number Date Country
2521719 Nov 1976 DE
3930451 Mar 1991 DE
4425015 Jan 1996 DE
296 09 350 Aug 1996 DE
195 37 084 Apr 1997 DE
296 19 029 Apr 1997 DE
19850671 May 1999 DE
10254668 Jun 2004 DE
69822877 Jan 2005 DE
202008000276 Jun 2008 DE
102009057921 Jun 2010 DE
0 502 268 Sep 1992 EP
0 515 867 Dec 1992 EP
543123 May 1993 EP
0 597 463 May 1994 EP
774926 Mar 1995 EP
0 650 701 May 1995 EP
0703461 Mar 1996 EP
0740926 Nov 1996 EP
0 754 437 Jan 1997 EP
923907 Jun 1999 EP
0 694 290 Nov 2000 EP
1149564 Oct 2001 EP
1041933 Mar 2004 EP
2313949 Jan 1977 FR
2037167 Jul 1980 GB
2 308 979 Jul 1997 GB
2 308 980 Jul 1997 GB
2 308 981 Jul 1997 GB
2 327 350 Jan 1999 GB
2 327 351 Jan 1999 GB
2 327 352 Jan 1999 GB
2331247 May 1999 GB
2379878 Mar 2003 GB
2408936 Jun 2005 GB
57-57802 Apr 1982 JP
57-117843 Jul 1982 JP
57-183850 Nov 1982 JP
63-40099 Aug 1988 JP
9-501328 Feb 1997 JP
9003152 Apr 1990 WO
9007303 Jul 1990 WO
9113650 Sep 1991 WO
9221278 Dec 1992 WO
9313816 Jul 1993 WO
9320747 Oct 1993 WO
9403134 Feb 1994 WO
9404220 Mar 1994 WO
9408654 Apr 1994 WO
9410924 May 1994 WO
9414383 Jul 1994 WO
9426228 Nov 1994 WO
9505780 Mar 1995 WO
9505781 Mar 1995 WO
9505867 Mar 1995 WO
9510326 Apr 1995 WO
9530373 Nov 1995 WO
9534259 Dec 1995 WO
9600042 Jan 1996 WO
9607360 Mar 1996 WO
9634568 Nov 1996 WO
9635469 Nov 1996 WO
9639914 Dec 1996 WO
9639962 Dec 1996 WO
9639964 Dec 1996 WO
9639965 Dec 1996 WO
9639967 Dec 1996 WO
9700646 Jan 1997 WO
9700647 Jan 1997 WO
9715238 May 1997 WO
9718765 May 1997 WO
9724073 Jul 1997 WO
9724074 Jul 1997 WO
9724992 Jul 1997 WO
9724993 Jul 1997 WO
9724994 Jul 1997 WO
9725101 Jul 1997 WO
9732551 Sep 1997 WO
9733523 Sep 1997 WO
9734540 Sep 1997 WO
9741786 Nov 1997 WO
9744071 Nov 1997 WO
9748345 Dec 1997 WO
9748346 Dec 1997 WO
9807468 Feb 1998 WO
9814131 Apr 1998 WO
9817185 Apr 1998 WO
9817186 Apr 1998 WO
9827877 Jul 1998 WO
9827879 Jul 1998 WO
9827880 Jul 1998 WO
9830144 Jul 1998 WO
9834550 Aug 1998 WO
9834558 Aug 1998 WO
9838925 Sep 1998 WO
9839038 Sep 1998 WO
9900060 Jan 1999 WO
9920185 Apr 1999 WO
9942037 Aug 1999 WO
9944506 Sep 1999 WO
9951155 Oct 1999 WO
9951158 Oct 1999 WO
0009053 Feb 2000 WO
0126570 Apr 2001 WO
0187154 May 2001 WO
0195819 Dec 2001 WO
0236028 May 2002 WO
02078557 Oct 2002 WO
03024339 Mar 2003 WO
2005125287 Dec 2005 WO
2008073727 Jun 2008 WO
2009094392 Jul 2009 WO
2011071482 Jun 2011 WO
Related Publications (1)
Number Date Country
20110077646 A1 Mar 2011 US